期刊文献+

A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma

A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma
原文传递
导出
摘要 Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting cellular tumor vaccines contribute to the induction of potent antitumor immune responses in murine models and patients suffering from cancers. Hepatocellular carcinoma (HCC) is one of the most frequent and malignant cancers in China. We describe, for the first time, a GM-CSF releasing vaccine strategy that represents a step toward combating this type of cancer. In this study, a bystander cell-based GM-CSF secreting vaccine against murine HCC, Hepa 1-6/B78H 1-GM-CSF, was co-administered with a low dose of cyclophosphamide (CY). After challenging with tumor and vaccination, immunological assays demonstrated that the cellular antitumor immune responses were efficiently activated and that tumor development was significantly retarded, which was dependent on synergy with CY. The promising outcome of the anti-HCC vaccine in the murine model demonstrates the feasibility of a future clinical application for this treatment in HCC patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting cellular tumor vaccines contribute to the induction of potent antitumor immune responses in murine models and patients suffering from cancers. Hepatocellular carcinoma (HCC) is one of the most frequent and malignant cancers in China. We describe, for the first time, a GM-CSF releasing vaccine strategy that represents a step toward combating this type of cancer. In this study, a bystander cell-based GM-CSF secreting vaccine against murine HCC, Hepa 1-6/B78H 1-GM-CSF, was co-administered with a low dose of cyclophosphamide (CY). After challenging with tumor and vaccination, immunological assays demonstrated that the cellular antitumor immune responses were efficiently activated and that tumor development was significantly retarded, which was dependent on synergy with CY. The promising outcome of the anti-HCC vaccine in the murine model demonstrates the feasibility of a future clinical application for this treatment in HCC patients.
出处 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2013年第4期349-359,共11页 中国免疫学杂志(英文版)
基金 This work was supported by grants from National Basic Research Program of China (2012CB910800 to BS), the National Natural Science Foundation (81072029 to BS and 30901750, 81272322 to YC, 81201528 to RJ), Major Research Plan of the National Natural Science Foundation (91029721 to BS), Natural Science Foundation of Jiangsu Province (BK2010532 to YC), China Postdoctoral Science Foundation-funded project (20090461133 to YC), Jiangsu Planned Projects for Postdoctoral Research Funds (1001028B to YC), Jiangsu Province Laboratory of Pathogen Biology (11BYKF02 to QS), Ministry of Health Research Foundation, China (LW201001 to LD) and the Priority Academic Program Development of Jiangsu Higher Education Institutions. The work was also supported in part by the Program for Development of Innovative Research Teams in the First Affiliated Hospital of NJMU.
关键词 cellular immunotherapy GM-CSF GVAX hepatocellular carcinoma T regulatory cells cellular immunotherapy GM-CSF GVAX hepatocellular carcinoma T regulatory cells
  • 相关文献

参考文献3

二级参考文献17

  • 1El-Serag HB, Rudolph KL. Hepatocellular carcinoma; epidemiology and molecular carcinogenesis. Gastro- enterology2007; 132: 2557-2576.
  • 2Munker R, Calin GA. MicroRNA profiling in cancer. Clin Sci (Lond) 20I 1; 121: 141-158.
  • 3Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H et al. MicroRNA-22 and microRNA-140 suppress NF-KB activity by regulating the expression of NF-~B coactivators. Biochem Biophys Res Commun 2011; 411: 826-831,.
  • 4Abelev GI, Production of embryonal serum alpha- globulin by hepatomas: review of experimental and clinical data. CancerRes 1968; 28: 1344-1350.
  • 5Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinico- pathological variables of HCC. J Gastroentero12010; 45: 1272-1282.
  • 6Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA et al. miR-122, a mammalian liver- specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
  • 7Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M etal. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
  • 8Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-240.
  • 9Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma Met al. MicroRNA122 is a key regula- tor of :z-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun 2011 ; 2: 338.
  • 10Peng SY, Chen W J, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112: 44-50.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部